Delivering erythropoietin through genetically engineered cells

Journal of the American Society of Nephrology

Volumn 11, Issue SUPPL. 16, 2000, Pages

  Bohl, D ^a   Heard, J M ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN F;

BETA THALASSEMIA; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; GENE TRANSFER; GENETIC ENGINEERING; HEMOGLOBINOPATHY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033759299     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. The molecular mechanism of erythropoietin action
2. Erythropoietin
3. Long-term secretion of therapeutic proteins from genetically modified skeletal muscles
4. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts
5. Stimulation of erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the human erythropoietin gene using an adenovirus vector
6. Stable delivery of physiological levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus
7. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector
8. Immune response to transgene-encoded proteins limits the stability of gene expression after injections of replication-defective adenovirus vectors
9. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immuno-competent mice
10. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
11. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation
12. Regulated gene expression systems
13. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
14. Transcriptional activation by tetracyclines in mammalian cells
15. Modulation of erythropoietin delivery from engineered muscles in mice
16. Long term control of erythropoietin secretion levels by tetracycline in mice transplanted with engineered primary myoblasts
17. Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer encapsulated engineered cells
18. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector
19. Regulation of gene expression in vivo following transduction by two separate rAAV vectors
20. Regulated delivery of therapeutic proteins after in vivo Somatic cell gene transfer
21. Effect of excess α-hemoglobin chains on cellular and membrane Oxidation in model β-thalassemic erythrocytes
22. Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias
23. Oxidative red blood cell membrane injury in the pathophysiology of severe mouse β-thalassemia
24. A majority of mice show long-term expression of a human β-globin after retrovirus transfer into hematopoietic stem cells
25. Regulated expression of a complete human β-globin gene encoded by a transmissible retrovirus vector
26. Lineage-specific expression of a human β-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells
27. Expression of the human beta globin gene following retroviral mediated transfer into multipotential hematopoietic progenitors of mice
28. Mutagenesis of retroviral vectors transducing human β-globin gene and β-globin locus control region derivatives results in stable transmission of an active transcriptional structure
29. Generation of a high-titer retroviral vector capable of expressing high levels of the human β-globin gene
30. Retroviral transfer of a human β-globin/γ-globin hybrid gene linked to β locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease
31. Treatment of thalassemia major with phenylbutyrate and hydroxyurea
32. Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley's anemia
33. Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis
34. Butyrate trials
35. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons
36. Cooperative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea
37. Administration of erythropoietin to patients with β-thalassemia intermedia: A preliminary trial
38. Trial of recombinant erythropoietin: Three patients with thalassemia intermedia
39. Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: A preliminary trial
40. Sustained increase in haemoglobin and RBC following long-term administration of recombinant erythropoietin to patients with homozygous β-thalassemia
41. Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia
42. Hydroxyurea therapy in thalassemia
43. A mouse model for β-thalassemia
44. Differential control of the synthesis of the two hemoglobin beta chains in normal mice
45. A murine model for the switch from fetal to adult hemoglobin during ontogeny
46. Increased synthesis of mouse minor hemoglobin in erythroid colonies: A cellular model for hemoglobin regulation
47. Increased mouse minor hemoglobin during erythroid stress: A model for hemoglobin regulation
48. A murine model for hemoglobin regulation: Hydroxyurea increases mouse minor hemoglobin in vivo
49. Improvement of mouse β-thalassemia by recombinant human erythropoietin
50. Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves the erythrocyte phenotype in murine beta thalassemia
51. Improvement of mouse β-thalassemia upon erythropoietin delivery by encapulated myoblasts
52. Improvement of erythropoiesis in β-thalassemic mice by continuous erythropoietin delivery from muscles